2 recruiting. 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Recruiting 2 |
Follow Liling Zhang: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Hypofractionation Radiotherapy in Combination With Glofitamab in Relapsed/Refractory Diffuse B-cell Lymphoma With Baseline High Tumor Burden Glofitamab + Obinutuzumab - Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL), Lymphoma | Phase 2 | Recruiting | Liling Zhang | 40 | 2025-04-01 | 2026-05-15 |
| Prospective, Single Arm, Single Center Study of Duvelisib Combined With Chidamide in the Treatment of Newly Diagnosed Peripheral T-cell Lymphoma (PTCL) Duvelisib, Chidamide - Newly Diagnosed Peripheral T-cell Lymphoma | Phase 2 | Recruiting | Liling Zhang | 36 | 2023-05-08 | 2026-05-18 |
Lymphoma (1) · Lymphoma, Large B-Cell, Diffuse (1) · Lymphoma, T-Cell, Peripheral (1)
N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide (1) · duvelisib (1) · glofitamab (1) · obinutuzumab (1)
China (2)